Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 3,945 | 15,529 | 13,907 | 4,359 | 0 |
| Gross Profit | 3,945 | 15,529 | 13,907 | 4,359 | N/A |
| Operating Expenses | 93,099 | 103,656 | 111,487 | 132,680 | 97,834 |
| Operating Income | -89,154 | -88,127 | -97,580 | -128,321 | -97,834 |
| Other Income | -41,726 | 1,243 | 1,640 | 132 | -10,548 |
| Pre-tax Income | -130,880 | -86,884 | -95,940 | -128,189 | -108,382 |
| Income Tax | 331 | 795 | 106 | 143 | 161 |
| Net Income Continuous | -131,211 | -87,679 | -96,046 | -128,332 | -108,543 |
| Net Income | $-131,211 | $-87,679 | $-96,046 | $-128,332 | $-108,543 |
| EPS Basic Total Ops | -20.94 | -34.20 | -56.25 | -80.50 | -271.75 |
| EPS Basic Continuous Ops | -20.94 | -34.21 | -56.24 | -80.50 | -271.68 |
| EPS Diluted Total Ops | -20.94 | -34.20 | -56.25 | -80.50 | -271.75 |
| EPS Diluted Continuous Ops | -20.94 | -34.21 | -56.24 | -80.50 | -271.68 |
| EPS Diluted Before Non-Recurring Items | -13.58 | -34.00 | -56.25 | -80.50 | -271.75 |
| EBITDA(a) | $-88,315 | $-85,482 | $-94,064 | $-124,457 | $-94,275 |